glp-1 obesity drug news today september 2025 Patients taking an experimental oral lost significant weight and improved heart and metabolic risk factors in a large, worldwide phase 3 clinical trial led by Weill Cornell Medicine and other What to Know About New

0.5% WL with placebo) [35], while phase 2 results for survodutide (4.8 mg weekly for 46 weeks) demonstrated an 18.7% reduction in bodyweight (vs

Recent studies using GLP1R/GIPR dual agonists, especially the SURPASS clinical trials, have revealed beneficial effects of GIP activation when used in conjunction with GLP-1RAs

Free radicals are unstable molecules that can damage collagen and elastin, leading to premature aging and dull skin

Longitudinal data were assessed using a linear mixed effects model, with group as a categorical variable and time as a continuous variable, and cross sectional data were assessed either by independent samples t -test or one-way ANOVA

I can say that my problems gradually disappeared.